Clinical trials: Rivaroxaban
COVID-19
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care…
- Trial name
- ECRU (NCT05088928)
- Testing
- Apixaban, Rivaroxaban
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Scotmann Pharmaceuticals
Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions.
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer
- Trial name
- H2H-OSCAR-US (NCT05461807)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban
- Where
- Germany
- Volunteers
- 2,437 people
- Sponsor
- Bayer
Bioequivalence
Bioequivalence of Xaroban 20mg (Rivaroxaban) Tablet and Xarelto 20mg (Rivaroxaban) Tablet Under Fed Conditions
A single center, open label, randomized, single-dose, two period, Two way cross-over study to explore the Bioequivalence of Test Product Xaroban (Rivaroxaban) 20 mg Tablet with the reference product Xarelto (Rivaroxaban) 20 mg…
- Trial name
- Bioequivalence (NCT04689919)
- Testing
- Rivaroxaban 20 MG Oral Tablet
- Where
- Pakistan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Karachi
Anticoagulants and Bleeding Disorders, Atrial Fibrillation
Atrial Fibrillation Research Database
All patients with atrial fibrillation who are treated with vitamin-k antagonists (warfarin, phenprocoumon) or non vitamin K oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in real world settings will be recorded…
- Trial name
- NCT03760874
- Where
- Italy
- Volunteers
- 5,000 people
- Sponsor
- University of Campania Luigi Vanvitelli
Nonvalvular Atrial Fibrillation
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk…
- Trial name
- NCT03374540
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- United States
- Volunteers
- 78,517 people
- Sponsor
- Bayer
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Coronary Artery Disease, Peripheral Artery Disease
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy
This is a phase IV, prospective biomarker study that will be conducted at Sinai Hospital of Baltimore. After screening for patients who were treated with aspirin, thirty patients will be treated with 81 mg enteric coated (EC)…
- Trial name
- NCT04059679
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- LifeBridge Health
Atrial Fibrillation, Thromboembolism, Venous
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Aim of the study is to investigate whether the influence of drugs inducing of CYP 3A4 isoenzyme of CYP450 and P-gp transporter significantly affect plasma levels of DOACs in patients with NVAF and venous thromboembolism
- Trial name
- NCT05750680
- Testing
- DOACs
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Acute DVT of Lower Extremity
Recanalization Rate of Acute DVT
Rporting and evaluation of the rate of recanalization of acute DVT of the lower limb at one year follow-up comparing the results of using NOACs vs. conventional treatment.
- Trial name
- NCT06145269
- Testing
- New oral anticoagulant (rivaroxaban) and Marevan (warfarin)
- Volunteers
- 100 people
- Sponsor
- Assiut University
Atrial Fibrillation
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
The purpose of this exploratory study is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult participants with non-valvular atrial fibrillation (NVAF) who undergo catheter ablation as…
- Trial name
- VENTURE-AF (NCT01729871)
- Testing
- rivaroxaban, uninterrupted vitamin K antagonist (VKA)
- Where
- 44 sites in United States, Belgium and 3 more
- Volunteers
- 253 people
- Sponsor
- Janssen Scientific Affairs, LLC
ST-segment Elevation Myocardial Infarction (STEMI), Left Ventricular Thrombus
Anti-CoagulaTion on Left Ventricular Thrombus After ST Segment Elevation Myocardial Infarction
Contemporary data are lacking regarding the management of left ventricular thrombus (LVT) developed after ST segment elevation myocardial infarction
- Trial name
- ACTonLVT (NCT05892042)
- Testing
- Rivaroxaban 15 MG [Xarelto]
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Jilin University
Post-Operative Atrial Fibrillation
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to…
- Trial name
- ATLAS (NCT02701062)
- Testing
- AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy
- Where
- 22 sites in United States
- Volunteers
- 562 people
- Sponsor
- AtriCure, Inc.
Venous Thromboembolism
Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism
Prospective, multicenter observational study, of the effectiveness of a standard of care protocol implemented to enhance home treatment of VTE.
- Trial name
- MATHVTE (NCT03404635)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 1,300 people
- Sponsor
- Indiana University
Atrial Fibrillation
Medical Need of OAC Reversal
This is a retrospective, observational, claims cohort study to assess, for adult patients initiating an oral anticoagulant for NVAF
- Trial name
- NCT03254147
- Testing
- warfarin, dabigatran, Apixaban
- Where
- Japan
- Volunteers
- 53,969 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Pulmonary Embolus
Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT05083455
- Testing
- Rivaroxaban, Enoxaparin
- Where
- United States
- Volunteers
- 89,215 people
- Sponsor
- Brigham and Women's Hospital
Deep Vein Thrombosis
Prophylactic Anticoagulation for Preventing Deep Vein Thrombosis After Total Hip Arthroplasty
Deep vein thrombosis (DVT) remains a life-threatening complication of arthroplasty. It remains controversial for anticoagulation strategies after total hip arthroplasty (THA).
- Trial name
- NCT01446887
- Testing
- prophylactic anticoagulation
- Where
- China
- Sponsor
- JIANG Qing
Healthy
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily…
- Trial name
- NCT04593784
- Testing
- Ciraparantag, Point-of-Care Coagulometer (investigational device)
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AMAG Pharmaceuticals, Inc.
Atrial Fibrillation
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
The purpose of the study is to compare the one-year and two-year risk of each of the following individual outcomes: Stroke and systemic embolism (SE), major bleeding and death between new users of anticoagulant for Stroke…
- Trial name
- BROTHER (NCT02864758)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists, dabigatran (Pradaxa)
- Where
- France
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Coagulation
Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer
The Perosphere Technologies' PoC Coagulometer measures clotting times of fresh whole blood samples. Clotting is initiated by glass surface activation and terminates on optical detection of fibrin assembly, the final step in the…
- Trial name
- NCT04868214
- Testing
- coagulation measurements
- Where
- 5 sites in United States, Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sciema UG